Literature DB >> 34489594

Programmable RNA targeting with the single-protein CRISPR effector Cas7-11.

Omar O Abudayyeh1, Jonathan S Gootenberg2, Ahsen Özcan3, Rohan Krajeski3, Eleonora Ioannidi3,4, Brennan Lee3, Apolonia Gardner3,5, Kira S Makarova6, Eugene V Koonin6.   

Abstract

CRISPR-Cas interference is mediated by Cas effector nucleases that are either components of multisubunit complexes-in class 1 CRISPR-Cas systems-or domains of a single protein-in class 2 systems1-3. Here we show that the subtype III-E effector Cas7-11 is a single-protein effector in the class 1 CRISPR-Cas systems originating from the fusion of a putative Cas11 domain and multiple Cas7 subunits that are derived from subtype III-D. Cas7-11 from Desulfonema ishimotonii (DiCas7-11), when expressed in Escherichia coli, has substantial RNA interference effectivity against mRNAs and bacteriophages. Similar to many class 2 effectors-and unique among class 1 systems-DiCas7-11 processes pre-CRISPR RNA into mature CRISPR RNA (crRNA) and cleaves RNA at positions defined by the target:spacer duplex, without detectable non-specific activity. We engineered Cas7-11 for RNA knockdown and editing in mammalian cells. We show that Cas7-11 has no effects on cell viability, whereas other RNA-targeting tools (such as short hairpin RNAs and Cas13) show substantial cell toxicity4,5. This study illustrates the evolution of a single-protein effector from multisubunit class 1 effector complexes, expanding our understanding of the diversity of CRISPR systems. Cas7-11 provides the basis for new programmable RNA-targeting tools that are free of collateral activity and cell toxicity.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34489594     DOI: 10.1038/s41586-021-03886-5

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  36 in total

Review 1.  Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.

Authors:  Addison V Wright; James K Nuñez; Jennifer A Doudna
Journal:  Cell       Date:  2016-01-14       Impact factor: 41.582

Review 2.  Development and applications of CRISPR-Cas9 for genome engineering.

Authors:  Patrick D Hsu; Eric S Lander; Feng Zhang
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.

Authors:  Alexandra East-Seletsky; Mitchell R O'Connell; Spencer C Knight; David Burstein; Jamie H D Cate; Robert Tjian; Jennifer A Doudna
Journal:  Nature       Date:  2016-09-26       Impact factor: 49.962

4.  RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex.

Authors:  Caryn R Hale; Peng Zhao; Sara Olson; Michael O Duff; Brenton R Graveley; Lance Wells; Rebecca M Terns; Michael P Terns
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.

Authors:  Sergey Shmakov; Omar O Abudayyeh; Kira S Makarova; Yuri I Wolf; Jonathan S Gootenberg; Ekaterina Semenova; Leonid Minakhin; Julia Joung; Silvana Konermann; Konstantin Severinov; Feng Zhang; Eugene V Koonin
Journal:  Mol Cell       Date:  2015-10-22       Impact factor: 17.970

6.  C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.

Authors:  Omar O Abudayyeh; Jonathan S Gootenberg; Silvana Konermann; Julia Joung; Ian M Slaymaker; David B T Cox; Sergey Shmakov; Kira S Makarova; Ekaterina Semenova; Leonid Minakhin; Konstantin Severinov; Aviv Regev; Eric S Lander; Eugene V Koonin; Feng Zhang
Journal:  Science       Date:  2016-06-02       Impact factor: 47.728

7.  Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.

Authors:  Poulami Samai; Nora Pyenson; Wenyan Jiang; Gregory W Goldberg; Asma Hatoum-Aslan; Luciano A Marraffini
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

Review 8.  Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.

Authors:  Kira S Makarova; Yuri I Wolf; Jaime Iranzo; Sergey A Shmakov; Omer S Alkhnbashi; Stan J J Brouns; Emmanuelle Charpentier; David Cheng; Daniel H Haft; Philippe Horvath; Sylvain Moineau; Francisco J M Mojica; David Scott; Shiraz A Shah; Virginijus Siksnys; Michael P Terns; Česlovas Venclovas; Malcolm F White; Alexander F Yakunin; Winston Yan; Feng Zhang; Roger A Garrett; Rolf Backofen; John van der Oost; Rodolphe Barrangou; Eugene V Koonin
Journal:  Nat Rev Microbiol       Date:  2019-12-19       Impact factor: 60.633

9.  RNA targeting by the type III-A CRISPR-Cas Csm complex of Thermus thermophilus.

Authors:  Raymond H J Staals; Yifan Zhu; David W Taylor; Jack E Kornfeld; Kundan Sharma; Arjan Barendregt; Jasper J Koehorst; Marnix Vlot; Nirajan Neupane; Koen Varossieau; Keiko Sakamoto; Takehiro Suzuki; Naoshi Dohmae; Shigeyuki Yokoyama; Peter J Schaap; Henning Urlaub; Albert J R Heck; Eva Nogales; Jennifer A Doudna; Akeo Shinkai; John van der Oost
Journal:  Mol Cell       Date:  2014-11-06       Impact factor: 17.970

10.  Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.

Authors:  Lin Wang; Junhu Zhou; Qixue Wang; Yunfei Wang; Chunsheng Kang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

View more
  20 in total

Review 1.  State-of-the-art CRISPR for in vivo and cell-based studies in Drosophila.

Authors:  Jonathan Zirin; Justin Bosch; Raghuvir Viswanatha; Stephanie E Mohr; Norbert Perrimon
Journal:  Trends Genet       Date:  2021-12-18       Impact factor: 11.639

2.  New Type III CRISPR variant and programmable RNA targeting tool: Oh, thank heaven for Cas7-11.

Authors:  Ryan J Catchpole; Michael P Terns
Journal:  Mol Cell       Date:  2021-11-04       Impact factor: 17.970

Review 3.  Targeted RNA editing: novel tools to study post-transcriptional regulation.

Authors:  Weijin Xu; Jeetayu Biswas; Robert H Singer; Michael Rosbash
Journal:  Mol Cell       Date:  2021-11-04       Impact factor: 17.970

4.  Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.

Authors:  Brandon Joseph Davis Burris; Adrian Moises Molina Vargas; Brandon J Park; Mitchell R O'Connell
Journal:  Methods       Date:  2022-08-17       Impact factor: 4.647

5.  High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.

Authors:  Huawei Tong; Jia Huang; Qingquan Xiao; Bingbing He; Xue Dong; Yuanhua Liu; Xiali Yang; Dingyi Han; Zikang Wang; Xuchen Wang; Wenqin Ying; Runze Zhang; Yu Wei; Chunlong Xu; Yingsi Zhou; Yanfei Li; Minqing Cai; Qifang Wang; Mingxing Xue; Guoling Li; Kailun Fang; Hainan Zhang; Hui Yang
Journal:  Nat Biotechnol       Date:  2022-08-11       Impact factor: 68.164

Review 6.  RNA-targeting CRISPR-Cas systems.

Authors:  Sam P B van Beljouw; Jasper Sanders; Alicia Rodríguez-Molina; Stan J J Brouns
Journal:  Nat Rev Microbiol       Date:  2022-09-28       Impact factor: 78.297

7.  Type III-A CRISPR systems as a versatile gene knockdown technology.

Authors:  Walter T Woodside; Nikita Vantsev; Ryan J Catchpole; Sandra C Garrett; Sara Olson; Brenton R Graveley; Michael P Terns
Journal:  RNA       Date:  2022-05-26       Impact factor: 5.636

8.  Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro.

Authors:  Leiping Zeng; Yanxia Liu; Xammy Huu Nguyenla; Timothy R Abbott; Mengting Han; Yanyu Zhu; Augustine Chemparathy; Xueqiu Lin; Xinyi Chen; Haifeng Wang; Draven A Rane; Jordan M Spatz; Saket Jain; Arjun Rustagi; Benjamin Pinsky; Adrianna E Zepeda; Anastasia P Kadina; John A Walker; Kevin Holden; Nigel Temperton; Jennifer R Cochran; Annelise E Barron; Michael D Connolly; Catherine A Blish; David B Lewis; Sarah A Stanley; Marie F La Russa; Lei S Qi
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

9.  Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.

Authors:  Renke Tan; Ryan K Krueger; Max J Gramelspacher; Xufei Zhou; Yibei Xiao; Ailong Ke; Zhonggang Hou; Yan Zhang
Journal:  Mol Cell       Date:  2022-01-19       Impact factor: 17.970

Review 10.  Drug delivery systems for RNA therapeutics.

Authors:  Kalina Paunovska; David Loughrey; James E Dahlman
Journal:  Nat Rev Genet       Date:  2022-01-04       Impact factor: 59.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.